Company intelligence / Profile preview

Selonterra

San Mateo, California, United Statesselonterra.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Selonterra has developed small molecule modulators targeting novel genetic mechanisms underlying neurodegenerative diseases. Their lead compounds restore gene expression dysfunctions associated with APOE4 in Alzheimer’s models and are advancing through lead optimization to IND-enabling studies. All pipeline programs are currently at the preclinical stage.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

APOE4 modulator

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Michael J. Fox Foundation for Parkinson's Research (grant funding partner)

Beyond the preview

Go deeper on Selonterra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selonterra.

Explore the full profile